Advertisement
Organisation › Details
Eisai (Group)
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. *
![]() |
Start | 1941-01-01 established |
![]() |
Industry | pharmaceutical |
![]() |
Region | Tokyo |
| Country | Japan | |
| Street | 4-6-10 Koishikawa, Bunkyo-ku | |
| City | n. a. Tokyo | |
| Address record changed: 2020-12-02 | ||
| Basic data | Employees | G: 5,001 to 10,000 (2019-09-20) |
| * Document for »About Section«: | ||
Record changed: 2025-03-16 |
Advertisement
More documents for Eisai (Group)
- [1] Merck & Co., Inc.. (4/21/26). "Press Release: Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)". Rahway, NJ & Nutley, NJ....
- [2] Eisai Co., Ltd.. (2/5/26). "Press Release: Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan". Tokyo & Shanghai....
- [3] Nuvation Bio Inc.. (1/12/26). "Press Release: Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan". New York, NY & Tokyo....
- [4] Newron Pharmaceuticals S.p.A.. (1/7/26). "Press Release: EA Pharma, a Subsidiary of Eisai, Announces the Initiation of Its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan". Milan & Morristown, NJ....
- [5] NICE (National Institute for Health and Care Excellence). (6/19/25). "Press Release: Final Draft Guidance Finds Benefits of 2 Alzheimer’s Treatments Remain too Small to Justify the Additional Cost to the NHS"....
- [6] BioArctic AB. (8/22/24). "Press Release: Leqembi (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain". Stockholm....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top



![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)




![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)


![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)


